22 November 2017
News and Views
Links and Services
A study in this month's Colorectal Disease reports improved efficacy at the cost of increased toxicity with FOLFOXIRI chemotherapy for the first-line treatment of metastatic colorectal cancer.
The simultaneous administration of irinotecan, 5-fluorouracil, folinic acid and oxaliplatin (FOLF
Email this page to a colleague
GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors